Therapeutic targeting of H19 may thus represent a promising strategy to enhance mitochondrial quality control and improve outcomes in infants with HLHS or other pediatric cardiac conditions characterized by ischemic stress. The gene discussed is H19; the disease is hypoplastic left heart syndrome.